Page 6 - Raches Ella News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Raches ella. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Raches Ella Today - Breaking & Trending Today

Why does Covaxin cost more than Covishield and Sputnik in India? — Quartz India

A new change in regulation has resurfaced old wounds about vaccine prices in India.
At Rs1,200 ($16.42) a dose, Bharat Biotech’s Covaxin, a Covid-19 vaccine fully developed and manufactured in India, is the most pricey option available at private hospitals in India. The vaccine is not only more expensive than the other locally manufactured option, Covishield, but costs more than even the imported Sputnik V.
Covaxin’s pricing is “nothing but governmental sanction for Bharat Biotech to make super profits,” says Malini Aisola, co-convener of the All India Drug Action Network (AIDAN), an independent collective of healthcare professionals and nonprofits. “These unethically inflated prices have no correlation to its cost of production,” she says. ....

Krishna Ella , Malini Aisola , Raches Ella , India Drug Action Network , Indian Council For Medical Research , Bharat Biotech , All India Drug Action Network , Indian Council , Medical Research , Narendra Modi , Covid 19 , Coronavirus India , Edited By Itika Sharma Punit , Indian Government , Modi Government , India Covid 19 , Covid 19 Vaccines , Serum Institute Of India , Health Ministry , Vaccine Diplomacy , Sputnik V , Vaccine Shortage , Vaccine Efficacy , கிருஷ்ணா எல்லா , மாலினி ஐசோழ , இந்தியா மருந்து நடவடிக்கை வலைப்பின்னல் ,

Covaxin's Phase 3 trials results likely next month; Bharat Biotech confident

The results of the third phase trials of India s first indigenously produced Covid-19 vaccine, Covaxin, are expected to be released next month. In India, Covaxin is now available in private hospitals in 28 locations. ....

Raches Ella , Suchitra Ella , Central Drugs Standard Control Organisation , Bharat Biotech , Mid March , Mid May , Joint Managing Director , Vaccination Drive , Third Phase , சூச்சித்ர எல்லா , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் , பாரத் பயோடெக் , நடுவில் அணிவகுப்பு , நடுவில் இருக்கலாம் , கூட்டு நிர்வகித்தல் இயக்குனர் , தடுப்பூசி இயக்கி , மூன்றாவது கட்டம் ,

Covaxin Phase-3 efficacy analysis to be made public by July: Bharat Biotech

Read more about Covaxin Phase-3 efficacy analysis to be made public by July: Bharat Biotech on Business Standard. The company is also doing phase-4 trials for real world effectiveness of the jab ....

Raches Ella , Indian Institute Of Medical Research , World Health Organisation , Bharat Biotech , Mid May , Indian Institute , Medical Research , Emergency Use List , Phase 3 Clinical Trial Data , Hase 4 Trials , இந்தியன் நிறுவனம் ஆஃப் மருத்துவ ஆராய்ச்சி , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , பாரத் பயோடெக் , நடுவில் இருக்கலாம் , இந்தியன் நிறுவனம் , மருத்துவ ஆராய்ச்சி , அவசரம் பயன்பாடு பட்டியல் ,

Covaxin trial data to be released in July, says Bharat Biotech, criticises study on antibody levels

A medical worker displays a vial of the Covaxin vaccine.
|
Indranil Mukherjee/AFP
Bharat Biotech, the manufacturer of coronavirus vaccine Covaxin, on Wednesday criticised a recent study that found that its jab produced significantly fewer antibodies than Covishield.
In a statement, the Hyderabad-based company claimed that the study “had lots of flaws”, ANI reported.
The company also said that the phase 3 trial data for Covaxin will be made public in July. The indigenously developed vaccine was granted an emergency use authorisation in January – despite there being no phase 3 trial data. The company had then said it would submit efficacy results by March. ....

Andhra Pradesh , Raches Ella , Central Drugs Standard Control Organisation , Bharat Biotech , Clinical Trial Registry , Central Drugs Standard Control , Bharat Biotech , Covaxin Trial Data , Harat Biotech On Covaxin Antibody , Ovaxin Antibody News , Bharat Biotech News , Covaxin News , ஆந்திரா பிரதேஷ் , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் , பாரத் பயோடெக் , மருத்துவ சோதனை பதிவு , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ,

Bharat Biotech to conduct Covaxin phase-4 trials to check real-world effectiveness | India News

Representative image
HYDERABAD: Bharat Biotech will be conducting phase-4 clinical trials of indigenously developed Covaxin to check its real-world effectiveness. It will also apply for full licensure for Covaxin only after it gets final analysis data of phase-3 studies, the company said on Wednesday.
According to the company, the phase-4 trials will not just help check the real-world effectiveness but also ensure that “its vaccine met every rigorous scientific standard for safety, effectiveness, and manufacturing quality needed to support emergency use authorization (EUA)”.
“It is important to note, the inoculation which began in mid-January and with several million doses administered, will have credible and sizable data soon,” it said. ....

West Bengal , Andhra Pradesh , Raches Ella , Awadhesh Kumar Singh , Indian Council Of Medical Research , Central Drugs Standard Control Organisation , Bharat Biotech , Indian Council , Medical Research , Ndia News , Ndia News Today , Oday News , Google News , Reaking News , மேற்கு பெங்கல் , ஆந்திரா பிரதேஷ் , அவதேஷ் குமார் சிங் , இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் , பாரத் பயோடெக் , இந்தியன் சபை , மருத்துவ ஆராய்ச்சி ,